随着国内医药行业的日渐成熟，国家监管体系的逐步完善，国内医药企业在最近几年得到了快速的发展。为了顺应市场需求，国内医药企业逐步提高质控体系的水平，目前有大量医药企业通过了国际FDA以及EDQM的认证，也就意味着这些药厂的产品可以出口到美国、欧洲、南美以及东南亚市场。按照国际标准广泛使用具有权威性的国际药典标准品，如美国药典USP、欧洲药典EP、英国药典BP、日本药典JP等，使用进口药典标准品作为对照品进行产品分析标定也是医药出口企业所必须进行的一项检测工作。
神经类部分产品如下：
拉莫三嗪Lamotrigine
Lamotrigine for peak identification
Lamotrigine for system suitability
Lamotrigine Imp. A (EP): 3-Amino-6-(2,3-dichlorophenyl)-1,2,4-triazin-5(4H)-one
Lamotrigine Related Compound B 2,3-dichlorobenzoic acid
Lamotrigine Related Compound C 3-amino-6-(2,3-dichlorophenyl)1,2,4-triazin-5(4H)-one
Lamotrigine Related Compound D N-[5-amino-6-(2,3-dichlorophenyl)-1,2,4-triazin-3-yl]-2,3-dichlorobenzamide
Lamotrigine impurity E 2,3-dichlorobenzoic acid
盐酸氟西汀Fluoxetine hydrochloride
Fluoxetine Related Compound A N-methyl-3-phenyl-3-[(alpha,alpha,alpha-(trifluoro-m-tolyl)oxy]propylamine HCl
Fluoxetine Related Compound B N-methyl-3-phenylpropylamine (Controlled Substance) Methyl-3-phenylpropylamin(1M-3PP)/(Methyl)(3-phenylpropyl)azan als Hydrochloride
Fluoxetine Related Compound C N-Methyl-N-[3-phenyl-3-(4-trifluoromethyl-phenoxy)-propyl] succinamic acid
米氮平Mirtazapine
Mirtazapine for system suitability
Mirtazapine Related Compound A 1,2,3,4,10,14b-hexahydropyrazino[2,1-a}pyrido[2,3-c][2]benzazepine
Mirtazapine Resolution Mixture
舒马曲坦Sumatriptan
Sumatriptan for system suitability
Sumatriptan impurity mixture
Sumatriptan Succinate Related Compound A [3-[2-(dimethylamino)ethyl]-2-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-1H-indol-5-yl]-N-methylmethansulfonamide, succinate salt
Sumatriptan Succinate Related Compound C [3-[2-(dimethylamino)ethyl]-1-(hydroxymethyl)-1H-indol-5-yl]- N-methylmethanesulfonamide succinate salt
更多详细信息，请咨询技术支持：
TEL：010-52457812/010-52457811/010-88482632
FAX：010-88482623
北京美同达科技有限公司
